These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 24523193)

  • 1. Targeted ex vivo reduction of CD64-positive monocytes in chronic myelomonocytic leukemia and acute myelomonocytic leukemia using human granzyme B-based cytolytic fusion proteins.
    Schiffer S; Rosinke R; Jost E; Hehmann-Titt G; Huhn M; Melmer G; Barth S; Thepen T
    Int J Cancer; 2014 Sep; 135(6):1497-508. PubMed ID: 24523193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Granzyme M as a novel effector molecule for human cytolytic fusion proteins: CD64-specific cytotoxicity of Gm-H22(scFv) against leukemic cells.
    Schiffer S; Letzian S; Jost E; Mladenov R; Hristodorov D; Huhn M; Fischer R; Barth S; Thepen T
    Cancer Lett; 2013 Dec; 341(2):178-85. PubMed ID: 23973499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel fully-human cytolytic fusion protein based on granzyme B shows in vitro cytotoxicity and ex vivo binding to solid tumors overexpressing the epidermal growth factor receptor.
    Niesen J; Hehmann-Titt G; Woitok M; Fendel R; Barth S; Fischer R; Stein C
    Cancer Lett; 2016 May; 374(2):229-40. PubMed ID: 26912070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Granzyme B-H22(scFv), a human immunotoxin targeting CD64 in acute myeloid leukemia of monocytic subtypes.
    Stahnke B; Thepen T; Stöcker M; Rosinke R; Jost E; Fischer R; Tur MK; Barth S
    Mol Cancer Ther; 2008 Sep; 7(9):2924-32. PubMed ID: 18790773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD64-directed microtubule associated protein tau kills leukemic blasts ex vivo.
    Mladenov R; Hristodorov D; Cremer C; Gresch G; Grieger E; Schenke L; Klose D; Amoury M; Woitok M; Jost E; Brümmendorf TH; Fendel R; Fischer R; Stein C; Thepen T; Barth S
    Oncotarget; 2016 Oct; 7(41):67166-67174. PubMed ID: 27564103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation of an artificial human B cell line test system using Transpo-mAbTM technology to evaluate the therapeutic efficacy of novel antigen-specific fusion proteins.
    Klose D; Woitok M; Niesen J; Beerli RR; Grawunder U; Fischer R; Barth S; Fendel R; Nachreiner T
    PLoS One; 2017; 12(7):e0180305. PubMed ID: 28704435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survivin expression, apoptosis and proliferation in chronic myelomonocytic leukemia.
    Invernizzi R; Travaglino E; Benatti C; Malcovati L; Della Porta M; Cazzola M; Ascari E
    Eur J Haematol; 2006 Jun; 76(6):494-501. PubMed ID: 16529600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Fc-alpha receptor is a new target antigen for immunotherapy of myeloid leukemia.
    Mladenov R; Hristodorov D; Cremer C; Hein L; Kreutzer F; Stroisch T; Niesen J; Brehm H; Blume T; Brümmendorf TH; Jost E; Thepen T; Fischer R; Stockmeyer B; Barth S; Stein C
    Int J Cancer; 2015 Dec; 137(11):2729-38. PubMed ID: 26041304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunophenotype in chronic myelomonocytic leukemia: is it closer to myelodysplastic syndromes or to myeloproliferative disorders?
    Subirá D; Font P; Villalón L; Serrano C; Askari E; Góngora E; Castañón S; Gonzalo R; Mata R; Román A; Llamas P
    Transl Res; 2008 May; 151(5):240-5. PubMed ID: 18433705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO Network.
    Itzykson R; Santini V; Thepot S; Ades L; Chaffaut C; Giagounidis A; Morabito M; Droin N; Lübbert M; Sapena R; Nimubona S; Goasguen J; Wattel E; Zini G; Torregrosa Diaz JM; Germing U; Pelizzari AM; Park S; Jaekel N; Metzgeroth G; Onida F; Navarro R; Patriarca A; Stamatoullas A; Götze K; Puttrich M; Mossuto S; Solary E; Gloaguen S; Chevret S; Chermat F; Platzbecker U; Fenaux P
    J Clin Oncol; 2023 Apr; 41(10):1888-1897. PubMed ID: 36455187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting cell-bound MUC1 on myelomonocytic, monocytic leukemias and phenotypically defined leukemic stem cells with anti-SEA module antibodies.
    Guillaume T; Dehame V; Chevallier P; Peterlin P; Garnier A; Grégoire M; Pichinuk E; Rubinstein DB; Wreschner DH
    Exp Hematol; 2019 Feb; 70():97-108. PubMed ID: 30593830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia.
    Emanuel PD
    Leukemia; 2008 Jul; 22(7):1335-42. PubMed ID: 18548091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensitivity to imatinib but low frequency of the TEL/PDGFRbeta fusion protein in chronic myelomonocytic leukemia.
    Gunby RH; Cazzaniga G; Tassi E; Le Coutre P; Pogliani E; Specchia G; Biondi A; Gambacorti-Passerini C
    Haematologica; 2003 Apr; 88(4):408-15. PubMed ID: 12681968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic myelomonocytic leukemia: myeloproliferative variant.
    Onida F; Beran M
    Curr Hematol Rep; 2004 May; 3(3):218-26. PubMed ID: 15087071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.
    Cortes J; Giles F; O'Brien S; Thomas D; Albitar M; Rios MB; Talpaz M; Garcia-Manero G; Faderl S; Letvak L; Salvado A; Kantarjian H
    Cancer; 2003 Jun; 97(11):2760-6. PubMed ID: 12767088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML).
    Wijermans PW; Rüter B; Baer MR; Slack JL; Saba HI; Lübbert M
    Leuk Res; 2008 Apr; 32(4):587-91. PubMed ID: 17881052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells.
    Metelitsa LS; Weinberg KI; Emanuel PD; Seeger RC
    Leukemia; 2003 Jun; 17(6):1068-77. PubMed ID: 12764370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and hematological aspects of chronic myelomonocytic leukemia. Study on 20 cases from a single center from Romania.
    Gologan R; Berceanu A; Colita A; Codreanu V; Dobrea C; Geoada L; Iacob V; Niculescu-Mizil E; Ostroveanu D; Puşcariu T; Ursuleac I
    Rom J Intern Med; 2002; 40(1-4):95-102. PubMed ID: 15526545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytotoxicity of anti-CD64-ricin a chain immunotoxin against human acute myeloid leukemia cells in vitro and in SCID mice.
    Zhong RK; van de Winkel JG; Thepen T; Schultz LD; Ball ED
    J Hematother Stem Cell Res; 2001 Feb; 10(1):95-105. PubMed ID: 11276363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NOX2-dependent immunosuppression in chronic myelomonocytic leukemia.
    Aurelius J; Hallner A; Werlenius O; Riise R; Möllgård L; Brune M; Hansson M; Martner A; Thorén FB; Hellstrand K
    J Leukoc Biol; 2017 Aug; 102(2):459-466. PubMed ID: 28292946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.